Long-term efficacy and safety of secukinumab in real life: a 240 weeks multicenter study from Southern Italy

References

• Megna M, Balato A, Napolitano M, et al. Psoriatic disease treatment nowadays: unmet needs among the “jungle of biologic drugs and small molecules”. Clin Rheumatol. 2018;37(7):1–6.
   PubMed Web of Science ®Google Scholar
• Sanford M, McKeage K. Secukinumab: first global approval. Drugs. 2015;75(3):329–338.
   PubMed Web of Science ®Google Scholar
• Bissonnette R, Luger T, Thaci D, et al. Secukinumab sustains good efficacy and favourable safety in moderate-to-severe psoriasis after up to 3 years of treatment: results from a double-blind extension study. Br J Dermatol. 2017;177(4):1033–1042.
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Kubanov A, van Doorn M, et al. Sustained efficacy of secukinumab in patients with moderate-to-severe palmoplantar psoriasis: 2.5-year results from GESTURE, a randomized, double-blind, placebo-controlled trial. Br J Dermatol. 2020;182(4):889–899.
   PubMed Web of Science ®Google Scholar
• Reich K, Sullivan J, Arenberger P, et al. Secukinumab shows high and sustained efficacy in nail psoriasis: 2.5-year results from the randomized placebo-controlled TRANSFIGURE study. Br J Dermatol. 2021;184(3):425–436.
   PubMed Web of Science ®Google Scholar
• Okubo Y, Ohtsuki M, Morita A, et al. Long-term efficacy and safety of secukinumab in japanese patients with moderate to severe plaque psoriasis: 3-year results of a double-blind extension study. J Dermatol. 2019;46(3):186–192.
   PubMed Web of Science ®Google Scholar
• Bissonnette R, Luger T, Thaci D, et al. Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE extension study). J Eur Acad Dermatol Venereol. 2018;32(9):1507–1514.
   PubMed Web of Science ®Google Scholar
• Cinelli E, Fabbrocini G, Megna M. Real-world experience versus clinical trials: pros and cons in psoriasis therapy evaluation. Int J Dermatol. 2022;61(3):e107–e108.
   PubMed Web of Science ®Google Scholar
• Masson Regnault M, Castañeda-Sanabria J, Diep Tran MHT, et al. Users of biologics in clinical practice: would they be eligible for phase III clinical studies? Cohort study in the French Psoriasis Registry PSOBIOTEQ. J Eur Acad Dermatol Venereol. 2020;34(2):293–300.
   PubMed Web of Science ®Google Scholar
• Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol. 2008;58(1):106–115.
   PubMed Web of Science ®Google Scholar
• Kimball AB, Papp KA, Wasfi Y, et al. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study. J Eur Acad Dermatol Venereol. 2013;27(12):1535–1545.
   PubMed Web of Science ®Google Scholar
• Langley RG, Lebwohl M, Krueger GG, et al. Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-to-severe psoriasis: results from the PHOENIX 2 study through 5 years of follow-up. Br J Dermatol. 2015;172(5):1371–1383.
   PubMed Web of Science ®Google Scholar
• Papp KA, Reich K, Paul C, et al. A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2016;175(2):273–286.
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Strober B, Menter A, et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med. 2015;373(14):1318–1328.
   PubMed Web of Science ®Google Scholar
• Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis–results of two phase 3 trials. N Engl J Med. 2014;371(4):326–338.
   PubMed Web of Science ®Google Scholar
• Megna M, Di Costanzo L, Argenziano G, et al. Effectiveness and safety of secukinumab in italian patients with psoriasis: an 84 week, multicenter, retrospective real-world study. Expert Opin Biol Ther. 2019;19(8):855–861.
   PubMed Web of Science ®Google Scholar
• Ruiz-Villaverde R, Rodriguez-Fernandez-Freire L, Galán-Gutierrez M, et al. Drug survival, discontinuation rates, and safety profile of secukinumab in real-world patients: a 152-week, multicenter, retrospective study. Int J Dermatol. 2020;59(5):633–639.
   PubMed Web of Science ®Google Scholar
• Megna M, Camela E, Cinelli E, et al. Real-life efficacy and safety of secukinumab in elderly patients with psoriasis over a 2-year period. Clin Exp Dermatol. 2020;45(7):848–852.
   PubMed Web of Science ®Google Scholar
• Galluzzo M, D’Adamio S, Silvaggio D, et al. In which patients the best efficacy of secukinumab? Update of a real-life analysis after 136 weeks of treatment with secukinumab in moderate-to-severe plaque psoriasis. Expert Opin Biol Ther. 2020;20(2):173–182.
   PubMed Web of Science ®Google Scholar
• Rompoti N, Sidiropoulou P, Panagakis P, et al. Real-world data from a single Greek Centre on the use of secukinumab in plaque psoriasis: effectiveness, safety, drug survival, and identification of patients that sustain optimal response. J Eur Acad Dermatol Venereol. 2020;34(6):1240–1247.
   PubMed Web of Science ®Google Scholar
• Chiricozzi A, Balato A, Conrad C, et al. Secukinumab demonstrates improvements in absolute and relative psoriasis area severity indices in moderate-to-severe plaque psoriasis: results from a european, multicentric, retrospective, real-world study. J Dermatolog Treat. 2020;31(5):476–483.
   PubMed Web of Science ®Google Scholar
• Rompoti N, Katsimbri P, Kokkalis G, et al. Real world data from the use of secukinumab in the treatment of moderate-to-severe psoriasis, including scalp and palmoplantar psoriasis: a 104-week clinical study. Dermatol Ther. 2019;32(5):e13006.
   PubMed Web of Science ®Google Scholar
• Finlay AY. Current severe psoriasis and the rule of tens. Br J Dermatol. 2005;152(5):861–867.
   PubMed Web of Science ®Google Scholar
• Basra MK, Fenech R, Gatt RM, et al. The Dermatology Life Quality Index 1994–2007: a comprehensive review of validation data and clinical results. Br J Dermatol. 2008;159(5):997–1035.
   PubMed Web of Science ®Google Scholar
• Belinchon Romero I, Dauden E, Ferrandiz Foraster C, et al. PASI 100 response rates in moderate to severe psoriasis: a systematic literature review and analysis of clinical practice guidelines. J Dermatolog Treat. 2022;33(3):1661–1669.
   PubMed Web of Science ®Google Scholar
• Mrowietz U, Kragballe K, Reich K, et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res. 2011;303(1):1–10.
   PubMed Web of Science ®Google Scholar
• Bożek A, Reich A. The reliability of three psoriasis assessment tools: psoriasis area and severity index, body surface area and physician global assessment. Adv Clin Exp Med. 2017;26(5):851–856.
   PubMed Web of Science ®Google Scholar
• Langley RG, Sofen H, Dei-Cas I, et al. Secukinumab long-term efficacy and safety in psoriasis through to year 5 of treatment: results of a randomized extension of the phase III ERASURE and FIXTURE trials. Br J Dermatol. 2023;188(2):198–207.
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Deodhar A, McInnes IB, et al. Long-term safety of secukinumab over five years in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis and ankylosing spondylitis: update on integrated pooled clinical trial and post-marketing surveillance data. Acta Derm Venereol. 2022;102:adv00698.
   PubMed Web of Science ®Google Scholar
• Augustin M, Sator PG, von Kiedrowski R, et al. Secukinumab demonstrated sustained retention, effectiveness and safety in a real-world setting in patients with moderate-to-severe plaque psoriasis: long-term results from an interim analysis of the SERENA study. J Eur Acad Dermatol Venereol. 2022;36(10):1796–1804.
   PubMed Web of Science ®Google Scholar
• Mendes-Bastos P, Morais P, Ferreira P, et al. Persistence, effectiveness, and real-world outcomes in psoriasis patients treated with secukinumab in Portugal. Dermatol Ther. 2022;35(7):e15510.
   PubMed Web of Science ®Google Scholar
• Diotallevi F, Gambini D, Radi G, et al. Should we be concerned about gastrointestinal-related adverse events in patients with plaque psoriasis receiving secukinumab therapy? A retrospective, real-life study. Dermatol Ther. 2022;35(11):e15794.
   PubMed Web of Science ®Google Scholar
• Huang YYM, Ruth JS, Hsu S. Loss of efficacy of secukinumab for psoriasis at 24 to 32 weeks. J Am Acad Dermatol. 2016;75(4):e169.
   PubMed Web of Science ®Google Scholar
• Galluzzo M, Talamonti M, De Simone C, et al. Secukinumab in moderate-to-severe plaque psoriasis: a multi-center, retrospective, real-life study up to 52 weeks observation. Expert Opin Biol Ther. 2018;18(7):727–735.
   PubMed Web of Science ®Google Scholar
• Georgakopoulos JR, Ighani A, Phung M, et al. Drug survival of secukinumab in real-world plaque psoriasis patients: a 52-week, multicenter, retrospective study. J Am Acad Dermatol. 2018;78(5):1019–1020.
   PubMed Web of Science ®Google Scholar
• Notario J, Deza G, Vilarrasa E, et al. Treatment of patients with plaque psoriasis with secukinumab in a real-life setting: a 52-week, multicenter, retrospective study in Spain. J Dermatolog Treat. 2019;30(5):424–429.
   PubMed Web of Science ®Google Scholar
• Li Y, Lu JJ, Zhong XY, et al. Drug survival outcomes associated with the real-world use of ixekizumab, secukinumab, guselkumab, and adalimumab for the treatment of plaque psoriasis in China: a 52-week single-center retrospective study. Clin Cosmet Investig Dermatol. 2022;15:2245–2252.
   PubMed Web of Science ®Google Scholar
• Egeberg A, Ottosen MB, Gniadecki R, et al. Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis. Br J Dermatol. 2018;178(2):509–519.
   PubMed Web of Science ®Google Scholar
• Mahil SK, Ezejimofor MC, Exton LS, et al. Comparing the efficacy and tolerability of biologic therapies in psoriasis: an updated network meta-analysis. Br J Dermatol. 2020;183(4):638–649.
   PubMed Web of Science ®Google Scholar
• Polivka L, Oubaya N, Bachelez H, et al. Trends in hospitalization rates for psoriasis flares since the introduction of biologics: a time series in France between 2005 and 2015. J Eur Acad Dermatol Venereol. 2018;32(11):1920–1929.
   PubMed Web of Science ®Google Scholar
• Megna M, Patruno C, Bongiorno MR, et al. Hepatitis virus reactivation in patients with psoriasis treated with secukinumab in a real-world setting of hepatitis B or hepatitis C infection. Clin Drug Investig. 2022;42(6):525–531.
   PubMed Web of Science ®Google Scholar